Guangzhou Wondfo BiotechLtd Gelecekteki Büyüme

Future kriter kontrolleri 5/6

Guangzhou Wondfo BiotechLtd kazanç ve gelirin sırasıyla yıllık 27.5% ve 21.1% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 26.9% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 13.9% olacağı tahmin edilmektedir.

Anahtar bilgiler

27.5%

Kazanç büyüme oranı

26.9%

EPS büyüme oranı

Medical Equipment kazanç büyümesi	26.5%
Gelir büyüme oranı	21.1%
Gelecekteki özkaynak getirisi	13.9%
Analist kapsamı	Low
Son güncelleme	29 Oct 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Returns On Capital At Guangzhou Wondfo BiotechLtd (SZSE:300482) Paint A Concerning Picture

Nov 18

Guangzhou Wondfo BiotechLtd's (SZSE:300482) Shareholders May Want To Dig Deeper Than Statutory Profit

Nov 01

Cautious Investors Not Rewarding Guangzhou Wondfo Biotech Co.,Ltd's (SZSE:300482) Performance Completely

Sep 06

Returns On Capital At Guangzhou Wondfo BiotechLtd (SZSE:300482) Paint A Concerning Picture

Jul 27

Guangzhou Wondfo BiotechLtd's (SZSE:300482) Solid Earnings May Rest On Weak Foundations

Apr 29

A Piece Of The Puzzle Missing From Guangzhou Wondfo Biotech Co.,Ltd's (SZSE:300482) Share Price

Mar 27

There Are Reasons To Feel Uneasy About Guangzhou Wondfo BiotechLtd's (SZSE:300482) Returns On Capital

Feb 29

Kazanç ve Gelir Büyüme Tahminleri

SZSE:300482 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (CNY Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	4,775	1,013	N/A	1,086	4
12/31/2025	3,951	818	N/A	917	4
12/31/2024	3,265	649	N/A	927	4
9/30/2024	2,942	524	107	538	N/A
6/30/2024	2,852	509	230	624	N/A
3/31/2024	2,794	502	289	664	N/A
12/31/2023	2,765	488	-104	329	N/A
9/30/2023	2,989	357	116	569	N/A
6/30/2023	3,136	354	-56	459	N/A
3/31/2023	3,887	497	1,268	1,818	N/A
1/1/2023	5,681	1,197	1,099	1,682	N/A
9/30/2022	5,550	1,247	905	1,472	N/A
6/30/2022	5,538	1,257	898	1,461	N/A
3/31/2022	5,290	1,383	-270	287	N/A
12/31/2021	3,361	634	208	665	N/A
9/30/2021	3,145	695	18	621	N/A
6/30/2021	3,060	741	-1	557	N/A
3/31/2021	2,956	692	113	594	N/A
12/31/2020	2,811	634	642	1,062	N/A
9/30/2020	2,821	663	657	886	N/A
6/30/2020	2,711	630	885	1,053	N/A
3/31/2020	2,172	413	595	775	N/A
12/31/2019	2,072	387	131	310	N/A
9/30/2019	1,921	375	175	329	N/A
6/30/2019	1,817	352	137	296	N/A
3/31/2019	1,748	325	97	232	N/A
12/31/2018	1,650	308	117	248	N/A
9/30/2018	1,542	280	69	198	N/A
6/30/2018	1,498	264	N/A	175	N/A
3/31/2018	1,323	231	N/A	186	N/A
12/31/2017	1,145	211	N/A	169	N/A
9/30/2017	921	181	N/A	51	N/A
6/30/2017	747	174	N/A	100	N/A
3/31/2017	624	154	N/A	116	N/A
12/31/2016	547	145	N/A	112	N/A
9/30/2016	525	158	N/A	143	N/A
6/30/2016	486	147	N/A	141	N/A
3/31/2016	450	131	N/A	145	N/A
12/31/2015	429	125	N/A	132	N/A
9/30/2015	382	106	N/A	108	N/A
6/30/2015	380	105	N/A	99	N/A
3/31/2015	365	96	N/A	107	N/A
12/31/2014	365	98	N/A	104	N/A
12/31/2013	248	59	N/A	101	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 300482 'nin tahmini kazanç büyümesi (yıllık 27.5% ) tasarruf oranının ( 2.8% ) üzerindedir.

Kazançlar ve Piyasa: 300482 şirketinin kazançlarının (yıllık 27.5% ) CN pazarından (yıllık 26.2% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: 300482 şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artması bekleniyor.

Gelir ve Pazar: 300482 şirketinin gelirinin (yıllık 21.1% ) CN pazarından (yıllık 13.9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 300482 şirketinin gelirinin (yıllık 21.1% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 300482 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 13.9 %).

Guangzhou Wondfo BiotechLtd Gelecekteki Büyüme

Future kriter kontrolleri 5/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target decreased by 7.6% to CN¥33.55

Price target decreased to CN¥60.42

Consensus revenue estimates increase by 34%

Price target decreased to CN¥68.96

Recent updates

Returns On Capital At Guangzhou Wondfo BiotechLtd (SZSE:300482) Paint A Concerning Picture

High number of new directors

Guangzhou Wondfo BiotechLtd's (SZSE:300482) Shareholders May Want To Dig Deeper Than Statutory Profit

Third quarter 2024 earnings released: EPS: CN¥0.17 (vs CN¥0.15 in 3Q 2023)

New minor risk - Share price stability

Guangzhou Wondfo Biotech Co.,Ltd to Report Q3, 2024 Results on Oct 25, 2024

Investor sentiment improves as stock rises 18%

Cautious Investors Not Rewarding Guangzhou Wondfo Biotech Co.,Ltd's (SZSE:300482) Performance Completely

Second quarter 2024 earnings released: EPS: CN¥0.29 (vs CN¥0.30 in 2Q 2023)

Returns On Capital At Guangzhou Wondfo BiotechLtd (SZSE:300482) Paint A Concerning Picture

Price target decreased by 7.6% to CN¥33.55

Guangzhou Wondfo Biotech Co.,Ltd to Report First Half, 2024 Results on Aug 14, 2024

Guangzhou Wondfo BiotechLtd's (SZSE:300482) Solid Earnings May Rest On Weak Foundations

Investor sentiment improves as stock rises 20%

First quarter 2024 earnings released: EPS: CN¥0.49 (vs CN¥0.46 in 1Q 2023)

New minor risk - Shareholder dilution

Guangzhou Wondfo Biotech Co.,Ltd to Report Q1, 2024 Results on Apr 22, 2024

A Piece Of The Puzzle Missing From Guangzhou Wondfo Biotech Co.,Ltd's (SZSE:300482) Share Price

There Are Reasons To Feel Uneasy About Guangzhou Wondfo BiotechLtd's (SZSE:300482) Returns On Capital

Investor sentiment deteriorates as stock falls 15%

Guangzhou Wondfo Biotech Co.,Ltd to Report Fiscal Year 2023 Results on Apr 22, 2024

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Guangzhou Wondfo Biotech Co.,Ltd to Report Q3, 2023 Results on Oct 26, 2023

Second quarter 2023 earnings released: EPS: CN¥0.30 (vs CN¥0.62 in 2Q 2022)

Guangzhou Wondfo Biotech Co.,Ltd (SZSE:300482) announces an Equity Buyback for CNY 50 million worth of its shares.

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Now 20% undervalued after recent price drop

Now 20% undervalued

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Now 23% undervalued

Price target decreased to CN¥60.42

Insufficient new directors

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.16 in 3Q 2021)

Investor sentiment improved over the past week

Guangzhou Wondfo Biotech Co.,Ltd (SZSE:300482) announces an Equity Buyback for CNY 50 million worth of its shares.

Second quarter 2022 earnings released: EPS: CN¥0.62 (vs CN¥0.90 in 2Q 2021)

Guangzhou Wondfo Biotech Co.,Ltd announced that it expects to receive CNY 1 billion in funding

Guangzhou Wondfo Biotech Co.,Ltd Announces Cash Dividend, Payable on 14 June 2022

Guangzhou Wondfo Biotech Co.,Ltd Approves Cash Dividend for the Year 2021

Consensus revenue estimates increase by 34%

Less than half of directors are independent

Guangzhou Wondfo Biotech Co.,Ltd. Announces Profit Distribution Proposal for 2021

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.27 in 3Q 2020)

Price target decreased to CN¥68.96

Guangzhou Wondfo Biotech Co.,Ltd (SZSE:300482) announces an Equity Buyback for CNY 80 million worth of its shares.

Second quarter 2021 earnings released: EPS CN¥0.90 (vs CN¥0.79 in 2Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Guangzhou Wondfo Biotech Co.,Ltd Announces 2020 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 26 May 2021

First quarter 2021 earnings released: EPS CN¥0.46 (vs CN¥0.29 in 1Q 2020)

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥1.87 (vs CN¥1.14 in FY 2019)

Guangzhou Wondfo Biotech Co.,Ltd to Report Fiscal Year 2020 Results on Mar 31, 2021

Wondfo Rams Up Neutralizing Antibody, Antigen and PCR Tests to Address the Evolving Demands for COVID-19 Testing Globally

New 90-day high: CN¥95.02

New 90-day high: CN¥90.79

Investor sentiment improved over the past week

New 90-day low: CN¥74.05

Third quarter earnings released

New 90-day low: CN¥81.99

New 90-day low: CN¥83.05

New 90-day low - CN¥84.82

First half earnings released

Guangzhou Wondfo Biotech Co.,Ltd to Report First Half, 2020 Results on Aug 28, 2020

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri